Steven D. Harr

2015 - Juno Therapeutics

In 2015, Steven D. Harr earned a total compensation of $3.4M as Chief Financial Officer and Head of Corporate Development at Juno Therapeutics, a 11% decrease compared to previous year.

Compensation breakdown

Bonus$112,000
Non-Equity Incentive Plan$208,000
Option Awards$2,701,300
Salary$400,000
Total$3,421,300

Harr received $2.7M in option awards, accounting for 79% of the total pay in 2015.

Harr also received $112K in bonus, $208K in non-equity incentive plan and $400K in salary.

Rankings

In 2015, Steven D. Harr's compensation ranked 2,674th out of 13,638 executives tracked by ExecPay. In other words, Harr earned more than 80.4% of executives.

ClassificationRankingPercentile
All
2,674
out of 13,638
80th
Division
Manufacturing
945
out of 5,187
82nd
Major group
Chemicals And Allied Products
345
out of 1,857
81st
Industry group
Drugs
270
out of 1,531
82nd
Industry
Biological Products, Except Diagnostic Substances
48
out of 260
82nd
Source: SEC filing on April 21, 2017.

Harr's colleagues

We found four more compensation records of executives who worked with Steven D. Harr at Juno Therapeutics in 2015.

2015

Hyam Levitsky

Juno Therapeutics

Chief Scientific Officer

2015

Robert Azelby

Juno Therapeutics

Executive Vice President, Chief Commercial Officer

2015

Hans Bishop

Juno Therapeutics

Chief Executive Officer

2015

Mark Frohlich

Juno Therapeutics

Executive Vice President, Portfolio Strategy

News

In-depth

You may also like